Last 4.75 MYR
Change Today -0.05 / -1.04%
Volume 60.8K
PHRM On Other Exchanges
Kuala Lumpur
As of 4:57 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

pharmaniaga berhad (PHRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/13 - 4.99
52 Week Low
08/28/13 - 4.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMANIAGA BERHAD (PHRM)

Related News

No related news articles were found.

pharmaniaga berhad (PHRM) Related Businessweek News

No Related Businessweek News Found

pharmaniaga berhad (PHRM) Details

Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare company primarily in Malaysia and Indonesia. It operates through Logistics and Distribution, and Manufacturing segments. The company is involved in the manufacture and sale of generic pharmaceutical products; supply, trading, and installation of medical and hospital equipment; trading and wholesale of consumer products; and distribution and trading of pharmaceutical products, medical products, food supplements, and diagnostic products. It also conducts research and development of pharmaceutical products, as well as provides hospital equipping services. The company is based in Shah Alam, Malaysia. Pharmaniaga Berhad is a subsidiary of Boustead Holdings Berhad.

pharmaniaga berhad (PHRM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmaniaga berhad (PHRM) Key Developments

Pharmaniaga Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Pharmaniaga announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported profit attributable to owners of parent of MYR 26,217,000 or 10.13 sen basic earnings per share on revenue of MYR 468,672,000 compared to profit attributable to owners of parent of MYR 24,771,000 or 9.57 sen basic earnings per share on revenue of MYR 500,339,000 of prior year period. Profit before taxation was MYR 38,159,000 against MYR 36,924,000 of prior year period. Net cash used in operating activities was MYR 7,359,000 against cash generated from operating activities of MYR 41,825,000 of prior year period. Purchase of property, plant and equipment amounted to MYR 7,1490,00 against MYR 5,820,000 of prior year period. Purchase of intangible assets was MYR 194,000 against MYR 968,000 of prior year period.

Pharmaniaga Bhd Declares First Interim Single Tier Dividend, Payable on June 6, 2014

Pharmaniaga Bhd declared a first interim single tier dividend of 4.00 Malaysian sen per share in respect of the year ended December 31, 2014. The dividend will be paid on June 6, 2014. The Ex-date is May 29, 2014 with entitlement date on June 2, 2014.

Pharmaniaga Bhd Announces the Resignation of Suriati Binti Ashari as Joint Secretary, Effective April 04, 2014

Pharmaniaga Bhd announced the resignation of Suriati binti Ashari as Joint Secretary, effective April 04, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHRM:MK 4.75 MYR -0.05

PHRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation PHRM Industry Range
Price/Earnings 22.3x
Price/Sales 0.7x
Price/Book 2.4x
Price/Cash Flow 18.9x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMANIAGA BERHAD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at